FR3143031B1 - Nouveaux peptides et leur utilisation en tant que transporteurs pour l’internalisation de molécules d’intérêt dans des cellules cibles - Google Patents

Nouveaux peptides et leur utilisation en tant que transporteurs pour l’internalisation de molécules d’intérêt dans des cellules cibles

Info

Publication number
FR3143031B1
FR3143031B1 FR2213003A FR2213003A FR3143031B1 FR 3143031 B1 FR3143031 B1 FR 3143031B1 FR 2213003 A FR2213003 A FR 2213003A FR 2213003 A FR2213003 A FR 2213003A FR 3143031 B1 FR3143031 B1 FR 3143031B1
Authority
FR
France
Prior art keywords
seq
interest
transporters
internalization
molecules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR2213003A
Other languages
English (en)
Other versions
FR3143031A1 (fr
Inventor
Jean-Luc Lenormand
Déborah Reynaud
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique
Grenoble Institute of Technology
Grenoble Alpes University
Original Assignee
Centre National de la Recherche Scientifique
Grenoble Institute of Technology
Grenoble Alpes University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique, Grenoble Institute of Technology, Grenoble Alpes University filed Critical Centre National de la Recherche Scientifique
Priority to FR2213003A priority Critical patent/FR3143031B1/fr
Priority to US19/132,319 priority patent/US20260193297A1/en
Priority to EP23836896.3A priority patent/EP4630059A1/fr
Priority to PCT/FR2023/051961 priority patent/WO2024121521A1/fr
Publication of FR3143031A1 publication Critical patent/FR3143031A1/fr
Application granted granted Critical
Publication of FR3143031B1 publication Critical patent/FR3143031B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L’invention concerne de nouveaux peptides de pénétration cellulaire comprenant ou consistant en une séquence d’acides aminés choisie parmi les séquences SEQ ID NO : 2, SEQ ID NO : 3, SEQ ID NO : 4, SEQ ID NO : 5, SEQ ID NO : 6, SEQ ID NO : 7 et SEQ ID NO : 8. L’invention concerne en outre des protéines de fusion comprenant lesdits peptides et une molécule d’intérêt pharmaceutique, diagnostic ou biotechnologique. Figure pour l’abrégé : Fig. 1
FR2213003A 2022-12-08 2022-12-08 Nouveaux peptides et leur utilisation en tant que transporteurs pour l’internalisation de molécules d’intérêt dans des cellules cibles Active FR3143031B1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
FR2213003A FR3143031B1 (fr) 2022-12-08 2022-12-08 Nouveaux peptides et leur utilisation en tant que transporteurs pour l’internalisation de molécules d’intérêt dans des cellules cibles
US19/132,319 US20260193297A1 (en) 2022-12-08 2023-12-08 New peptides and use thereof as delivery systems for internalization of molecules of interest into target cells
EP23836896.3A EP4630059A1 (fr) 2022-12-08 2023-12-08 Nouveaux peptides et leur utilisation en tant que transporteurs pour l'internalisation de molécules d'intérêt dans des cellules cibles
PCT/FR2023/051961 WO2024121521A1 (fr) 2022-12-08 2023-12-08 Nouveaux peptides et leur utilisation en tant que transporteurs pour l'internalisation de molécules d'intérêt dans des cellules cibles

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2213003 2022-12-08
FR2213003A FR3143031B1 (fr) 2022-12-08 2022-12-08 Nouveaux peptides et leur utilisation en tant que transporteurs pour l’internalisation de molécules d’intérêt dans des cellules cibles

Publications (2)

Publication Number Publication Date
FR3143031A1 FR3143031A1 (fr) 2024-06-14
FR3143031B1 true FR3143031B1 (fr) 2026-06-05

Family

ID=86604608

Family Applications (1)

Application Number Title Priority Date Filing Date
FR2213003A Active FR3143031B1 (fr) 2022-12-08 2022-12-08 Nouveaux peptides et leur utilisation en tant que transporteurs pour l’internalisation de molécules d’intérêt dans des cellules cibles

Country Status (4)

Country Link
US (1) US20260193297A1 (fr)
EP (1) EP4630059A1 (fr)
FR (1) FR3143031B1 (fr)
WO (1) WO2024121521A1 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011135222A2 (fr) 2010-04-26 2011-11-03 Universite Joseph Fourier Utilisation de peptides comme transporteurs destines a l'internalisation de molecules d'interet dans des cellules cibles
AU2013316679B2 (en) * 2012-09-13 2017-12-14 Les Hopitaux Universitaires De Geneve Cell penetrating peptides
WO2016146143A1 (fr) * 2015-03-16 2016-09-22 Amal Therapeutics Sa Peptides pénétrant dans les cellules et complexes comprenant ceux-ci
US20190085404A1 (en) * 2016-03-04 2019-03-21 The Board Of Trustees Of The Leland Stanford Junior University Methods of identifying and treating immune checkpoint inhibitor-responsive neoplasms and cells, transgenic animals and kits for use therein

Also Published As

Publication number Publication date
FR3143031A1 (fr) 2024-06-14
WO2024121521A1 (fr) 2024-06-13
US20260193297A1 (en) 2026-07-09
EP4630059A1 (fr) 2025-10-15

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20240614

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4